Early Biologic Treatment in Pediatric Crohn’s Disease: Catchingthe Therapeutic Window of Opportunity in Early Disease by Treat-to-Target

키워드

참고문헌 (70)

1. Baumgart DC, "Inflammatory bowel disease: clinical aspects and established and evolving therapies", Lancet, 369, pp.1641~1657 (2007)[DOI]
2. Cosnes J, "Long-term evolution of disease behavior of Crohn's disease", Inflamm Bowel Dis, 8, pp.244~250 (2002)[DOI]
3. Thia KT, "Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort", Gastroenterology, 139, pp.1147~1155 (2010)[DOI]
4. Rosen MJ, "Inflammatory bowel disease in children and adolescents", JAMA Pediatr, 169, pp.1053~1060 (2015)[DOI]
5. 김승, "Surgery in Pediatric Crohn’s Disease: Indications, Timing and Post-Operative Management", Pediatric Gastroenterology, Hepatology & Nutrition, 20(1), pp.14~21 (2017), 대한소아소화기영양학회
6. Walters TD, "Mechanisms of growth impairment in pediatric Crohn's disease", Nat Rev Gastroenterol Hepatol, 6, pp.513~523 (2009)[DOI]
7. Walters TD, "Can early anti-TNF-<TEX>${\alpha}$<", TEX> treatment be an effective therapeutic strategy in children with Crohn's disease?, 2014, pp.6, 799~802
8. Hanauer SB, "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial", Lancet, 359, pp.1541~1549 (2002)[DOI]
9. Sands BE, "Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study", Clin Gastroenterol Hepatol, 2, pp.912~920 (2004)[DOI]
10. Hyams J, "Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children", Gastroenterology, 132, pp.863~873 (2007)[DOI]
11. Colombel JF, "Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial", Gastroenterology, 132, pp.52~65 (2007)[DOI]
12. Hyams JS, "Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children", Gastroenterology, 143, pp.365~374 (2012)[DOI]
13. Ordas I, "Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change", Gut, 60, pp.1754~1763 (2011)[DOI]
14. Antunes O, "Treatment algorithms in Crohn's - up, down or something else?", Best Pract Res Clin Gastroenterol, 28, pp.473~483 (2014)[DOI]
15. Neurath MF, "Mucosal healing in inflammatory bowel diseases: a systematic review", Gut, 61, pp.1619~1635 (2012)[DOI]
16. Rutgeerts P, "Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease", Gastroenterology, 126, pp.402~413 (2004)[DOI]
17. Froslie KF, "Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort", Gastroenterology, 133, pp.412~422 (2007)[DOI]
18. Baert F, "Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease", Gastroenterology, 138, pp.463~468 (2010)[DOI]
19. De Cruz P, "Mucosal healing in Crohn's disease: a systematic review", Inflamm Bowel Dis, 19, pp.429~444 (2013)[DOI]
20. Frolkis AD, "Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies", Gastroenterology, 145, pp.996~1006 (2013)[DOI]
21. Smolen JS, "Treating rheumatoid arthritis to target: recommendations of an international task force", Ann Rheum Dis, 69, pp.631~637 (2010)[DOI]
22. Allen PB, "Preventing disability in inflammatory bowel disease", Therap Adv Gastroenterol, 10, pp.865~876 (2017)[DOI]
23. Peyrin-Biroulet L, "Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process", Am J Gastroenterol, 107, pp.1770~1776 (2012)[DOI]
24. Pariente B, "Development of the Crohn's disease digestive damage score, the Lemann score", Inflamm Bowel Dis, 17, pp.1415~1422 (2011)[DOI]
25. Danese S, "Catching the therapeutic window of opportunity in early Crohn's disease", Curr Drug Targets, 15, pp.1056~1063 (2014)[DOI]
26. D'Haens G, "Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial", Lancet, 371, pp.660~667 (2008)[DOI]
27. Colombel JF, "Infliximab, azathioprine, or combination therapy for Crohn's disease", N Engl J Med, 362, pp.1383~1395 (2010)[DOI]
28. Khanna R, "Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial", Lancet, 386, pp.1825~1834 (2015)[DOI]
29. Colombel JF, "Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease-a SONIC post hoc analysis", Aliment Pharmacol Ther, 41, pp.734~746 (2015)[DOI]
30. Colombel JF, "Adalimumab induces deep remission in patients with Crohn's disease", Clin Gastroenterol Hepatol, 12, pp.414~422 (2014)[DOI]
31. Walters TD, "Increased effectiveness of early therapy with anti-tumor necrosis factor-<TEX>${\alpha}$<", TEX> vs an immunomodulator in children with Crohn's disease, 2014, pp.146, 383~391
32. Kang B, "Mucosal healing in paediatric patients with moderate- to-severe luminal crohn's disease under combined immunosuppression: escalation versus early treatment", J Crohns Colitis, 10, pp.1279~1286 (2016)[DOI]
33. Kierkus J, "The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderateto-severe Crohn's disease", Eur J Gastroenterol Hepatol, 24, pp.495~500 (2012)[DOI]
34. Nobile S, "Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center", Eur J Gastroenterol Hepatol, 26, pp.458~465 (2014)[DOI]
35. Nuti F, "Prospective evaluation of the achievement of mucosal healing with anti-TNF-<TEX>${\alpha}$<", TEX> therapy in a paediatric Crohn's disease cohort, 2016, pp.10, 5~12
36. Desreumaux P, "Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease", Gastroenterology, 113, pp.118~126 (1997)[DOI]
37. Kugathasan S, "Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease", Gut, 56, pp.1696~1705 (2007)[DOI]
38. Borrelli O, "Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease", Dig Liver Dis, 36, pp.342~347 (2004)[DOI]
39. Crombe V, "Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study", Inflamm Bowel Dis, 17, pp.2144~2152 (2011)[DOI]
40. Church PC, "Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease", Inflamm Bowel Dis, 20, pp.1177~1186 (2014)[DOI]
41. Jaeyoung Choi, "Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn’s Disease Patients", Gut and Liver, 12(3), pp.255~262 (2018), 거트앤리버 소화기연관학회협의회
42. Lee YM, "Infliximab "Top-Down" strategy is superior to "Step-Up" in maintaining long-term remission in the treatment of pediatric crohn disease", J Pediatr Gastroenterol Nutr, 60, pp.737~743 (2015)[DOI]
43. Wauters L, "Long-term outcomes with anti-TNF therapy and accelerated step-up in the prospective pediatric belgian crohn's disease registry (BELCRO)", Inflamm Bowel Dis, 23, pp.1584~1591 (2017)[DOI]
44. Kugathasan S, "Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study", Lancet, 389, pp.1710~1718 (2017)[DOI]
45. Kotlyar DS, "A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease", Clin Gastroenterol Hepatol, 9, pp.36~41 (2011)[DOI]
46. Ruemmele FM, "Consensus guidelines of ECCO", ESPGHAN on the medical management of pediatric Crohn's disease, 2014, pp.8, 1179~1207
47. Kopylov U, "Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a quebec claims database study", Inflamm Bowel Dis, 21, pp.1847~1853 (2015)[DOI]
48. Kandiel A, "Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine", Gut, 54, pp.1121~1125 (2005)[DOI]
49. Siegel CA, "Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a metaanalysis", Clin Gastroenterol Hepatol, 7, pp.874~881 (2009)[DOI]
50. Dulai PS, "Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review", Clin Gastroenterol Hepatol, 12, pp.1443~1451 (2014)[DOI]
51. Hyams JS, "Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease", Gastroenterology, 152, pp.1901~1914 (2017)[DOI]
52. Cozijnsen MA, "Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease", Inflamm Bowel Dis, 21, pp.951~961 (2015)[DOI]
53. Feagan BG, "Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease", Gastroenterology, 146, pp.681~688 (2014)[DOI]
54. Toruner M, "Risk factors for opportunistic infections in patients with inflammatory bowel disease", Gastroenterology, 134, pp.929~936 (2008)[DOI]
55. Marehbian J, "Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease", Am J Gastroenterol, 104, pp.2524~2533 (2009)[DOI]
56. Andrew S. Day, "The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease", Journal of Pediatric Gastroenterology and Nutrition, 66(2), pp.361~368 (2018), Ovid Technologies (Wolters Kluwer Health)[DOI]
57. Bouguen G, "Treat to target: a proposed new paradigm for the management of Crohn's disease", Clin Gastroenterol Hepatol, 13, pp.1042~1050 (2015)[DOI]
58. Van Assche G, "The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations", J Crohns Colitis, 4, pp.63~101 (2010)[DOI]
59. Beaugerie L, "Predictors of Crohn's disease", Gastroenterology, 130, pp.650~656 (2006)[DOI]
60. Louis E, "Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2", CARD15 genotype, 2003, pp.52, 552~557
61. Romberg-Camps MJ, "Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease", Am J Gastroenterol, 104, pp.371~383 (2009)[DOI]
62. Allez M, "Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy", Am J Gastroenterol, 97, pp.947~953 (2002)
63. Peyrin-Biroulet L, "First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?", Nat Rev Gastroenterol Hepatol, 10, pp.345~351 (2013)[DOI]
64. Dubinsky MC, "Increased immune reactivity predicts aggressive complicating Crohn's disease in children", Clin Gastroenterol Hepatol, 6, pp.1105~1111 (2008)[DOI]
65. Abreu MT, "Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease", Gastroenterology, 123, pp.679~688 (2002)[DOI]
66. Cleynen I, "Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project", Gut, 62, pp.1556~1565 (2013)[DOI]
67. Siegel CA, "Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease", Inflamm Bowel Dis, 17, pp.30~38 (2011)[DOI]
68. Dubinsky M, "Have we changed the natural history of pediatric Crohn's disease with biologics?", Dig Dis, 32, pp.360~363 (2014)[DOI]
69. Peyrin-Biroulet L, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target", Am J Gastroenterol, 110, pp.1324~1338 (2015)[DOI]
70. Zubin G, "Predicting endoscopic crohn's disease activity before and after induction therapy in children: a comprehensive assessment of PCDAI, CRP, and fecal calprotectin", Inflamm Bowel Dis, 21, pp.1386~1391 (2015)

관련 논문AI추천